GU Cancers 2024 | Upcoming biomarkers in renal cell carcinoma

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT, provides an overview of developments in biomarkers for renal cell carcinoma (RCC). With the advent of therapies for metastatic RCC, especially in the adjuvant setting, biomarkers are needed to identify patients who will benefit from such therapies. Various techniques such as evaluating tissue histology and single cell genomics will enable clinicians to elucidate novel and usable biomarkers. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.